M. Rigdon Lentz, M.D. received his Bachelors degree from the University of Tennessee with a major in Biology. He graduated from the U.S. Naval Aviation Officer Candidate School, receiving the “Distinguished Naval Graduate” award. He became a Naval Flight Instructor in Pensacola, Florida where he was elected “Instructor of the Year” and received the Medical Officer Scholarship Award for medicine.
Dr. Lentz graduated cum laude from Georgetown University Medical School in 1975, was elected to AOA honor medical society and received the Mosby Scholarship award.
Dr. Lentz completed his internship in General Surgery, residency in Internal Medicine and fellowship in Hematology/Oncology at the Naval Medical Center in San Diego, and later served as Chief of Oncology at the Naval Medical Center in Long Beach, California. Dr. Lentz was subsequently appointed Assistant Professor of Medicine at the University of California, San Diego, and Associate Professor of Medicine at the University of California, Irvine.
While at the Naval Medical Center, he maintained a full-time clinical practice in Hematology and Oncology, simultaneously serving as Chairman of the Hematology-Oncology Department, Chairman of the Tumor Board, Chairman of the Cancer Committee, Chairman of the Tumor Registry, Chairman of the Disaster Preparedness Committee, and Member of the Executive and Credentials Committees.
Dr. Lentz subsequently served as Principal investigator of the U.S. Naval Leukopenia Research Project Phase 1, 2 and 3 studies, conducting both clinical and laboratory research. He has headed multiple cancer centers in his career, and been Principal Investigator of Phase 1 and 2 clinical trials for both drugs and medical devices.
He is credited with the discovery of post-translational regulation of pro-inflammatory cytokines in cancer through shedding of membrane receptors. This discovery led to the development of the anti-inflammatory drug Enbrel. He has been awarded numerous international patents for Methods and Systems to reverse immune tolerance in cancers and infectious disease.
Dr. Lentz has published over 20 peer-reviewed papers, co-authored two major textbooks and been an invited speaker at more than 100 major international conferences, lecturing on the subject of cytokine modulation in advanced cancers.
He currently serves as Director of the non-profit International Immunology Foundation, and consults for various international life science and biotechnology companies.
Dr. Lentz continues to engage in R&D to improve the efficacy of OncoPherese treatment and extend the duration of remission once attained, for the benefit of patients and their families. He also trains other physicians in clinical applications of tumor immunology.
I would like to take this opportunity to thank you … for the care and comfort you have provided for my wife over the past months.
The Doctors, Nurses and Staff couldn’t have been more warm, gracious and hospitable.
I support you, your work and your treatment and can give no greater recommendation to others. AM, PH.D.
We’re open from 9:00 a.m. to 5:00 p.m. Central European Time (Eastern Standard Time + 6 hours).
From within Germany: +49-8051-909-300
From EU to Germany: +49-8051-909-300
From the U.S.: 011-49-8051-909-300
From within Germany: +49-8051-909-301
From EU to Germany: +49-8051-909-301
From the U.S.: 011-49-8051-909-301